Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease
characterized by a wide variability of clinical manifestations and a course frequently subject …

Objective Despite the pivotal role that hydroxychloroquine (HCQ) plays in treating systemic
lupus erythematosus (SLE), less than 50% of patients take HCQ as prescribed …

Systemic lupus erythematosus (SLE) is usually described as a disease that most often
strikes reproductive-age women. However, the onset of SLE beyond the age of 50 years is …

Significant fatigue is reported by two-thirds of patients with SLE and severe fatigue by one-
third. The assessment and treatment of fatigue remains a major challenge in SLE, especially …

Systemic lupus erythematosus (SLE) is a chronic immune-mediated inflammatory
multisystem disease. The onset of viral and bacterial infections may favor the exacerbation …

Autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, autoimmune hepatitis
and inflammatory bowel disease, have complex pathogeneses and the factors which cause …

Hydroxychloroquine has unique immunomodulatory properties and an attractive adverse
effect profile. Over the past 10 years, research has led to significant updates in clinical …

There have been many advances in the diagnosis and therapeutic management of systemic
lupus erythematosus (SLE) over the past decades. Following more than eleven centuries of …

Mycophenolic acid (MPA) has become the cornerstone in the treatment of lupus nephritis.
However, response rates are still far from ideal in clinical trials. Uncertainty exists regarding …

B-cells abnormalities leading to autoantibody production play a central role in Systemic
Lupus Erythematosus (SLE) pathogenesis. B-cell targeted therapies, including anti-B …